Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice

The significant and growing global prevalence of diabetes continues to challenge people with diabetes (PwD), healthcare providers, and payers. While maintaining near-normal glucose levels has been shown to prevent or delay the progression of the long-term complications of diabetes, a significant proportion of PwD are not attaining their glycemic goals. During the past 6 years, we have seen tremendous advances in automated insulin delivery (AID) technologies. Numerous randomized controlled trials and real-world studies have shown that the use of AID systems is safe and effective in helping PwD achieve their long-term glycemic goals while reducing hypoglycemia risk. Thus, AID systems have recently become an…

• A
  Amgen
• EL
  Eli Lilly and Company
• S
  Sanofi
• LM
  Leona M. and Harry B. Helmsley Charitable Trust
• BB
  Bigfoot Biomedical
• IC
  Insulet Corporation
• D
  Dexcom
• TD
  Tandem Diabetes Care
• NN
  Novo Nordisk
• RD
  Roche Diabetes Care
• AD
  Abbott Diabetes Care